Androgen deprivation is the predominant therapy for advanced prostate cancer.
There is accumulating evidence that phases of intermission in androgen deprivation may have benefits regarding side effects, albeit there is as yet no general recommendation for intermittent androgen deprivation therapy. Recent systematic reviews at least substantiate a benefit from such regimens for general quality of life without therapy compromisation. In addition, preclinical data revealed further potential strategies for intermittent androgen deprivation therapy. Future studies must prove, however, that such approaches can be implemented in the clinical situation.
Written by:
Thelen P, Ringert RH, Loertzer H, Strauß A. Are you the author?
Urologische Klinik und Poliklinik, Georg-August-Universität Göttingen, Robert-Koch-Straße 40, 37075, Göttingen, Deutschland.
Reference: Urologe A. 2012 Apr 21. Epub ahead of print.
doi: 10.1007/s00120-012-2870-1
PubMed Abstract
PMID: 22526181
Article in German.